results
Jump to
136 Results Found
  • Dr Reddy’s Lab Q4 PAT may dip 13.6% YoY to Rs. 674.5 cr: Sharekhan Apr 12, 2021 08:42 PM IST

    Dr Reddy’s Lab Q4 PAT may dip 13.6% YoY to Rs. 674.5 cr: Sharekhan

    Net Sales are expected to increase by 9 percent Y-o-Y (down 1.9 percent Q-o-Q) to Rs. 4,849.3 crore, according to Sharekhan.

  • Dr Reddy's Labs Q3 preview: YoY rise in sales, profit expected; updates on niche ANDA filings, new launches to be in focus Jan 29, 2021 07:28 AM IST

    Dr Reddy's Labs Q3 preview: YoY rise in sales, profit expected; updates on niche ANDA filings, new launches to be in focus

    Brokerage firm Kotak Institutional Equities expects the company's US business to increase by $8 mn quarter-on-quarter (QoQ) to $255 mn, led by the launch of Kuvan.

  • Dr. Reddy’s Lab Q3 PAT to Rs. 729.7 cr: Yash Securities Jan 22, 2021 01:02 PM IST

    Dr. Reddy’s Lab Q3 PAT to Rs. 729.7 cr: Yash Securities

    Net Sales are expected to increase by 16.5 percent Y-o-Y (up 4.3 percent Q-o-Q) to Rs. 5,121.8 crore, according to Yash Securities.

  • Dr. Reddy’s Laboratories Q3 PAT may dip 2% YoY to Rs. 781.6 cr: Prabhudas Lilladher Jan 18, 2021 11:05 PM IST

    Dr. Reddy’s Laboratories Q3 PAT may dip 2% YoY to Rs. 781.6 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 12.3 percent Y-o-Y (up 0.5 percent Q-o-Q) to Rs. 4,397.1 crore, according to Prabhudas Lilladher.

  • Dr Reddy's Labs Q1 Preview: Profit may decline on higher base, but revenue can grow over 5% Jul 29, 2020 09:21 AM IST

    Dr Reddy's Labs Q1 Preview: Profit may decline on higher base, but revenue can grow over 5%

    Sharekhan sees 167 bps increase in EBITDA margin due to cost savings and better revenue performance.

  • Dr Reddy's Labs reports strong operating performance in Q3: Key highlights from concall Jan 28, 2020 06:49 PM IST

    Dr Reddy's Labs reports strong operating performance in Q3: Key highlights from concall

    The company has filed 20 formulations across the global markets, with three Abbreviated New Drug Application (ANDAs) in the US. It has filed 20 Drug Master Files (DMFs) across the markets, with three DMFs in the US.

  • Dr Reddy's hits over 3-year high as analysts remain positive, raise target post Q3 show Jan 28, 2020 11:37 AM IST

    Dr Reddy's hits over 3-year high as analysts remain positive, raise target post Q3 show

    HSBC also maintained buy call on the stock and raised price target to Rs 3,430 (from Rs 3,230 earlier)

  • Dr. Reddy’s Q2 PAT may dip 10% YoY to Rs. 455.9 cr: Emkay Oct 14, 2019 03:56 PM IST

    Dr. Reddy’s Q2 PAT may dip 10% YoY to Rs. 455.9 cr: Emkay

    Net Sales are expected to increase by 9.7 percent Y-o-Y (up 8.4 percent Q-o-Q) to Rs. 4,167.1 crore, according to Emkay.

  • Dr. Reddy’s Laboratories Q1 PAT seen up 13.6% YoY to Rs. 540.8 cr: Prabhudas Lilladher Jul 12, 2019 04:50 PM IST

    Dr. Reddy’s Laboratories Q1 PAT seen up 13.6% YoY to Rs. 540.8 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 2.2 percent Y-o-Y (down 5.2 percent Q-o-Q) to Rs. 3,820.3 crore, according to Prabhudas Lilladher.

  • Dr Reddy's Q4 preview: Profit to rise 37% YoY to Rs 413cr; EBITDA margin may touch 23% May 17, 2019 09:27 AM IST

    Dr Reddy's Q4 preview: Profit to rise 37% YoY to Rs 413cr; EBITDA margin may touch 23%

    Narnolia Financial Advisors expects the pharma company to report a net profit of Rs 545 crore as against Rs 500 crore in the last quarter

  • Dr Reddy’s Laboratories Q4 PAT seen up 36.9% YoY to Rs. 413.6 cr: Kotak Apr 17, 2019 03:15 PM IST

    Dr Reddy’s Laboratories Q4 PAT seen up 36.9% YoY to Rs. 413.6 cr: Kotak

    Net Sales are expected to increase by 7.7 percent Y-o-Y (down 1.1 percent Q-o-Q) to Rs. 3,807.5 crore, according to Kotak.

  • Dr. Reddy’s Laboratories Q4 PAT seen up 88.4% YoY to Rs. 512.7 cr: Prabhudas Lilladher Apr 12, 2019 01:00 PM IST

    Dr. Reddy’s Laboratories Q4 PAT seen up 88.4% YoY to Rs. 512.7 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 12.4 percent Y-o-Y (up 3.4 percent Q-o-Q) to Rs. 3,994.3 crore, according to Prabhudas Lilladher.

  • Dr Reddy's climbs 3% even as analysts view on Q3 earnings mixed Feb 04, 2019 12:35 PM IST

    Dr Reddy's climbs 3% even as analysts view on Q3 earnings mixed

    While maintaining buy call with a price target at Rs 2,704, Japanese brokerage firm Nomura said company's operating performance was ahead of its expectations.

  • Dr Reddy's Q3 preview: Analysts expect strong profit but moderate revenue growth Feb 01, 2019 08:30 AM IST

    Dr Reddy's Q3 preview: Analysts expect strong profit but moderate revenue growth

    Kotak, which sees 2.4% growth in topline, also forecasts 12% YoY growth for India

  • Dr. Reddy’s Lab Q3 PAT seen up 60.6% YoY to Rs. 472.4 cr: Sharekhan Jan 18, 2019 03:00 PM IST

    Dr. Reddy’s Lab Q3 PAT seen up 60.6% YoY to Rs. 472.4 cr: Sharekhan

    Net Sales are expected to increase by 1.9 percent Y-o-Y (up 2.3 percent Q-o-Q) to Rs. 3,905 crore, according to Sharekhan.

  • Dr. Reddys Q3 PAT seen up 37.7% YoY to Rs. 416.9 cr: ICICI Direct Jan 11, 2019 05:33 PM IST

    Dr. Reddys Q3 PAT seen up 37.7% YoY to Rs. 416.9 cr: ICICI Direct

    Net Sales are expected to increase by 4.7 percent Y-o-Y (up 5.2 percent Q-o-Q) to Rs. 4,015.2 crore, according to ICICI Direct.

  • Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila Jan 04, 2019 10:45 AM IST

    Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

    For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.

  • Dr Reddy’s Q2 review: Brokerages term results to be in line with estimates; Citi rises target to Rs 2,680 Oct 29, 2018 02:35 PM IST

    Dr Reddy’s Q2 review: Brokerages term results to be in line with estimates; Citi rises target to Rs 2,680

    The pharma major reported a rise of 77 percent (year-on-year) in its net profit at Rs 503.8 crore. The company had reported a profit of Rs 284.9 crore during the same period of last year.

  • Dr Reddy’s Q2 preview: Brokerages expect subdued show, profit likely around Rs 330-370 cr Oct 26, 2018 09:12 AM IST

    Dr Reddy’s Q2 preview: Brokerages expect subdued show, profit likely around Rs 330-370 cr

    The effect of Suboxone based on US court order is likely to weigh as well.

  • Dr. Reddy’s Labs Q2 PAT seen up 32% YoY to Rs. 380 cr: HDFC Securities Oct 17, 2018 05:40 PM IST

    Dr. Reddy’s Labs Q2 PAT seen up 32% YoY to Rs. 380 cr: HDFC Securities

    Net Sales are expected to increase by 10.8 percent Y-o-Y (up 5.6 percent Q-o-Q) to Rs. 3,930 crore, according to HDFC Securities.

  • Dr. Reddy’s Lab Q2 PAT seen up 20.2% YoY to Rs. 356.1 cr: Sharekhan Oct 17, 2018 11:23 AM IST

    Dr. Reddy’s Lab Q2 PAT seen up 20.2% YoY to Rs. 356.1 cr: Sharekhan

    Net Sales are expected to increase by 5.3 percent Y-o-Y (up 0.4 percent Q-o-Q) to Rs. 3,750 crore, according to Sharekhan.

  • Dr. Reddys Q2 PAT seen up 18.2% YoY to Rs. 361.1 cr: ICICI Direct Oct 12, 2018 04:41 PM IST

    Dr. Reddys Q2 PAT seen up 18.2% YoY to Rs. 361.1 cr: ICICI Direct

    Net Sales are expected to increase by 8.4 percent Y-o-Y (up 3.2 percent Q-o-Q) to Rs. 3,857.7 crore, according to ICICI Direct.

  • Dr Reddy’s Laboratories Q1 PAT seen up 421.7% YoY to Rs. 308.3 cr: Kotak Jul 18, 2018 02:24 PM IST

    Dr Reddy’s Laboratories Q1 PAT seen up 421.7% YoY to Rs. 308.3 cr: Kotak

    Net Sales are expected to increase by 9.7 percent Y-o-Y (up 2.9 percent Q-o-Q) to Rs. 3,638.8 crore, according to Kotak.

  • Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz Jul 12, 2018 09:42 PM IST

    Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz

    "For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities

  • Dr. Reddy’s Lab Q4 PAT may dip 17.7% YoY to Rs. 269.4 cr: KR Choksey Apr 23, 2018 03:17 PM IST

    Dr. Reddy’s Lab Q4 PAT may dip 17.7% YoY to Rs. 269.4 cr: KR Choksey

    Net Sales are expected to increase by 11.1 percent Y-o-Y (down 3.7 percent Q-o-Q) to Rs. 3,663.7 crore, according to KR Choksey.

Sections